Evidence map›Paper›PMID 28434209›Full record

ArticleClinical endocrinology2017

Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus.

Sang Soo Kim, Sang Heon Song, Jong Ho Kim, Yun Kyung Jeon, Bo Hyun Kim, Min-Cheol Kang, Sung Wan Chun, Soo Hyun Hong, Michelle Chung, Yong Ki Kim and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Sang Soo KimDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Sang Heon SongDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Jong Ho KimDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Yun Kyung JeonDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Bo Hyun KimDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Min-Cheol KangDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Sung Wan ChunDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Soo Hyun HongDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Michelle ChungDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Yong Ki KimKim Yong Ki Internal Medicine Clinic, Busan, Korea.
In Joo KimDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Young-Bum KimDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9471-6330
Beth Israel Deaconess Medical Center · USPusan National University Hospital · KR

Funding

ApoJ as a novel hepatokine targeting muscle glucose metabolismR01DK111529 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIM, YOUNG-BUM · 2016 to 2020
$2.2M
NIDDK NIH HHS R01 DK111529
6 · The paper itself

Abstract

objectiveThe objective of this study was to evaluate the association of urine clusterin/apolipoprotein J (Apo J) with the development and/or progression of diabetic kidney disease (DKD) in type 2 diabetes. MATERIALS AND

methodsA total of 159 type 2 diabetic patients and 20 nondiabetic subjects with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m

resultsBaseline clusterin levels in urine were significantly increased in type 2 diabetic subjects compared with those of nondiabetic subjects. The levels of urine clusterin had a significant correlation with urine tubular damage markers. A positive correlation between the annual rate of decline in eGFR and urine clusterin after adjusting for clinical confounding factors was detected. Multivariate analysis further indicated that urine clusterin correlated with the development of CKD stage 3 or greater and persistence/progression of albuminuria. In type 2 diabetic subjects with albuminuria, urine clusterin remained associated with the annual decline rate in eGFR and the progression of CKD stage.

conclusionsUrine clusterin reflects tubular damage in the early stage of DKD. The increase in urine clusterin along with albuminuria could be an independent predictive marker for the progression of DKD in type 2 diabetes.

Indexed as

AdultAgedAlbuminuriaCase-Control StudiesClusterinDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleGlomerular Filtration RateHumansKidney TubulesMaleMiddle AgedRisk FactorsCLU protein, humanClusterinalbuminuriaclusterindiabetic nephropathyglomerular filtration rateproteinuria

Identifiers

PMID28434209
PMCPMC5511063
OpenAlexW2607266784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.